WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) announced today a new policy statement regarding interactions between BIO’s healthcare-related member companies and healthcare professionals. The policy, approved last week by BIO’s Health Section Governing Board, encourages each of BIO’s members involved in the marketing of biologics or other pharmaceuticals to United States healthcare professionals to adopt “a transparent and rigorous code of conduct,” which also “ensures compliance with all applicable local, state and federal laws and regulations.”
